Abstract
Nuo Wang, Hongwei Jiang, Zhang Fang, Jiajin Ma, Lujun Chen, Shaoxian Wu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
10.1016/j.ejca.2022.09.031 · 2022
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies
10.1158/1078-0432.ccr-22-2241 · 2024
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
10.1200/jco.21.02885 · 2023
Addressing cancer's grand challenges
10.1038/d41573-020-00202-0 · 2020
Therapeutic targeting of regulatory T cells in cancer
10.1016/j.trecan.2022.06.008 · 2022
FOXP3+ regulatory T cells in the human immune system
10.1038/nri2785 · 2010
PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis
10.1080/2162402x.2020.1729299 · 2020
Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy
10.1186/s13287-022-02829-9 · 2022
Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1172/jci180893 · 2025
Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies
10.1016/j.immuni.2025.03.021 · 2025
CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
10.1038/s43018-020-00133-0 · 2020
CD103(+) regulatory T cells underlie resistance to radio-immunotherapy and impair CD8(+) T cell activation in glioblastoma
10.1038/s43018-023-00547-6 · 2023
Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
10.1016/j.immuni.2024.07.010 · 2024
FOXP3(+) regulatory T cell perturbation mediated by the IFNγ-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity
10.1038/s41467-023-44391-9 · 2024
Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling
10.1038/s41467-024-54874-y · 2024
Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunity
10.1038/s41467-025-56002-w · 2025
A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion
10.1016/j.ymthe.2024.09.010 · 2024
Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis
10.1038/s41423-023-01107-9 · 2023
A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases
10.1016/j.cell.2023.04.025 · 2023
AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model
10.1158/1535-7163.mct-05-0310 · 2006
AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
10.1038/nature07710 · 2009
An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome
10.1038/ni.1702 · 2009
Immunobiology and structural biology of AIM2 inflammasome
10.1016/j.mam.2020.100869 · 2020
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
10.1038/nature07725 · 2009
Inflammasome: structure, biological functions, and therapeutic targets
10.1002/mco2.391 · 2023
Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis
10.1111/imr.13406 · 2025
Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells
10.3390/ijms23042230 · 2022
AIM2 in regulatory T cells restrains autoimmune diseases
10.1038/s41586-021-03231-w · 2021
Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
10.1016/j.ccell.2024.05.013 · 2024
PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
10.1073/pnas.1822001116 · 2019
Myeloid-derived suppressor cells in cancer and cancer therapy
10.1038/s41571-023-00846-y · 2024
Succinate-loaded tumor cell-derived microparticles reprogram tumor-associated macrophage metabolism
10.1126/scitranslmed.adr4458 · 2025
AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma
10.1084/jem.20200962 · 2021
Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation
2022
Targeting the metabolism of tumor-infiltrating regulatory T cells
10.1016/j.it.2023.06.001 · 2023
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
10.1186/s12967-024-05104-y · 2024
EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment
10.1016/j.cyto.2019.154951 · 2020
TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2
10.1016/j.celrep.2023.113231 · 2023
NLRP3 Attenuates Intraocular Inflammation by Inhibiting AIM2-Mediated Pyroptosis Through the Phosphorylated Salt-Inducible Kinase 1/Sterol Regulatory Element Binding Transcription Factor 1 Pathway
10.1002/art.42420 · 2023
Overexpressed CD44 is associated with B-cell activation via the HA-CD44-AIM2 pathway in lupus B cells
10.1016/j.clim.2023.109710 · 2023
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy
10.1016/j.ccell.2024.04.011 · doi-reference
Hand in hand to successful immunotherapy: CD8(+) T cells and M1-like macrophages swap the baton
10.1016/j.ccell.2024.05.012 · doi-reference
Targeting lipid metabolism of macrophages: A new strategy for tumor therapy
10.1016/j.jare.2024.02.009 · doi-reference
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy
10.1186/s13045-024-01559-0 · doi-reference
Metabolism, metabolites, and macrophages in cancer
10.1186/s13045-023-01478-6 · doi-reference
Murine regulatory T cells utilize granzyme B to promote tumor metastasis
10.1007/s00262-023-03410-w · doi-reference
Spatial profiling technologies illuminate the tumor microenvironment
10.1016/j.ccell.2023.01.010 · doi-reference
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses
10.1016/j.immuni.2022.02.005 · doi-reference
CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool
10.1158/2159-8290.cd-23-1263 · doi-reference
Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer
10.1146/annurev-immunol-082223-044122 · doi-reference